Primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) are chronic liver diseases that likely have an autoimmune basis to their pathogenesis. [1,2,3 ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

PBC is a rare disease characterized by the inflammation of the intrahepatic bile ducts leading to cholestasis, which may ultimately result in cirrhosis and chronic liver disease. PSC is another ...

For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver ... For primary sclerosing cholangitis there are no ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...

It's one of the primary symptoms of a rare, progressive liver disease called primary sclerosing cholangitis or PSC. This disease is often diagnosed in the prime of life, but people may not even ...

1 Academic Liver Unit and Research Laboratory of Internal Medicine ... pattern are highly specific for primary biliary cirrhosis (PBC). Aim and subjects: To assess the prevalence of PBC specific ANAs, ...

The American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2025 are: About 42,240 new cases (28,220 in men and 14,020 in women) will be ...